Javascript must be enabled to continue!
Lung function trajectories in patients with idiopathic pulmonary fibrosis
View through CrossRef
Abstract
Background
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterised by decline in lung function. We evaluated trajectories of forced vital capacity (FVC) and diffusing capacity (DLco) in a cohort of patients with IPF.
Methods
Patients with IPF that was diagnosed or confirmed at the enrolling centre in the previous 6 months were enrolled into the IPF-PRO Registry between June 2014 and October 2018. Patients were followed prospectively, with lung function data collected as part of routine clinical care. Mean trajectories of FVC and DLco % predicted in all patients and in subgroups by characteristics assessed at enrolment were estimated using a joint model that accounted for factors such as disease severity and visit patterns.
Results
Of 1002 patients in the registry, 941 had ≥ 1 FVC and/or DLco measurement after enrolment. The median (Q1, Q3) follow-up period was 35.1 (18.9, 47.2) months. Overall, mean estimated declines in FVC and DLco % predicted were 2.8% and 2.9% per year, respectively. There was no evidence that the mean trajectories of FVC or DLco had a non-linear relationship with time at the population level. Patients who were male, white, had a family history of ILD, were using oxygen, or had prior/current use of antifibrotic therapy at enrolment had greater rates of decline in FVC % predicted. Patients who were male or white had greater rates of decline in DLco % predicted.
Conclusions
Data from the IPF-PRO Registry suggest a constant rate of decline in lung function over a prolonged period, supporting the inexorably progressive nature of IPF. A graphical abstract summarising the data in this manuscript is available at: https://www.usscicomms.com/respiratory/IPF-PRORegistry_LungFunctionTrajectories.
Trial registration
NCT01915511.
Springer Science and Business Media LLC
Title: Lung function trajectories in patients with idiopathic pulmonary fibrosis
Description:
Abstract
Background
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterised by decline in lung function.
We evaluated trajectories of forced vital capacity (FVC) and diffusing capacity (DLco) in a cohort of patients with IPF.
Methods
Patients with IPF that was diagnosed or confirmed at the enrolling centre in the previous 6 months were enrolled into the IPF-PRO Registry between June 2014 and October 2018.
Patients were followed prospectively, with lung function data collected as part of routine clinical care.
Mean trajectories of FVC and DLco % predicted in all patients and in subgroups by characteristics assessed at enrolment were estimated using a joint model that accounted for factors such as disease severity and visit patterns.
Results
Of 1002 patients in the registry, 941 had ≥ 1 FVC and/or DLco measurement after enrolment.
The median (Q1, Q3) follow-up period was 35.
1 (18.
9, 47.
2) months.
Overall, mean estimated declines in FVC and DLco % predicted were 2.
8% and 2.
9% per year, respectively.
There was no evidence that the mean trajectories of FVC or DLco had a non-linear relationship with time at the population level.
Patients who were male, white, had a family history of ILD, were using oxygen, or had prior/current use of antifibrotic therapy at enrolment had greater rates of decline in FVC % predicted.
Patients who were male or white had greater rates of decline in DLco % predicted.
Conclusions
Data from the IPF-PRO Registry suggest a constant rate of decline in lung function over a prolonged period, supporting the inexorably progressive nature of IPF.
A graphical abstract summarising the data in this manuscript is available at: https://www.
usscicomms.
com/respiratory/IPF-PRORegistry_LungFunctionTrajectories.
Trial registration
NCT01915511.
Related Results
Multimodality imaging of chronic thromboembolic pulmonary hypertension : new insights into old challenges
Multimodality imaging of chronic thromboembolic pulmonary hypertension : new insights into old challenges
<p dir="ltr"><b>BACKGROUND:</b><br><br>Most forms of pulmonary hypertension carry unsatisfactory prognosis with the notable exception of chronic throm...
Multimodality imaging of chronic thromboembolic pulmonary hypertension : new insights into old challenges
Multimodality imaging of chronic thromboembolic pulmonary hypertension : new insights into old challenges
<p dir="ltr"><b>BACKGROUND:</b><br><br>Most forms of pulmonary hypertension carry unsatisfactory prognosis with the notable exception of chronic throm...
Bone Marrow Fibrosis in Patients with Inherited Bone Marrow Failure Syndromes.
Bone Marrow Fibrosis in Patients with Inherited Bone Marrow Failure Syndromes.
Abstract
Abstract 3192
Poster Board III-129
Introduction
Bone marrow fibrosis has been reported in...
Blunt Chest Trauma and Chylothorax: A Systematic Review
Blunt Chest Trauma and Chylothorax: A Systematic Review
Abstract
Introduction: Although traumatic chylothorax is predominantly associated with penetrating injuries, instances following blunt trauma, as a rare and challenging condition, ...
Lung Fibrosis after COVID-19: Treatment Prospects
Lung Fibrosis after COVID-19: Treatment Prospects
At the end of 2019, a highly contagious infection began its ominous conquest of the world. It was soon discovered that the disease was caused by a novel coronavirus designated as S...
The loss of IL-31 signaling attenuates bleomycin-induced pulmonary fibrosis
The loss of IL-31 signaling attenuates bleomycin-induced pulmonary fibrosis
Idiopathic Pulmonary Fibrosis (IPF) is a severe fibrotic lung disease characterized by excessive collagen deposition and progressive decline in lung function. Th2 T cell-derived cy...
Perceptions, experiences and needs of patients with idiopathic pulmonary fibrosis
Perceptions, experiences and needs of patients with idiopathic pulmonary fibrosis
AbstractAimsTo understand the perceptions, needs and experiences of patients with Idiopathic Pulmonary Fibrosis.BackgroundIdiopathic pulmonary fibrosis is a progressive interstitia...
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract
Introduction
Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...

